Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.51 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002177 | 1.00 | PPARG (0.51) | PPARGGPR132OXER1LTB4R2ALDH1A1 | |
| SCHEMBL2997989 | 0.89 | PPARG (0.43) | PPARGGPR132OXER1LTB4R2ALDH1A1 | |
| SCHEMBL2997984 | 0.89 | PPARG (0.43) | PPARGGPR132OXER1LTB4R2ALDH1A1 | |
| SCHEMBL29969208 | 0.82 | OXER1 (0.67) | PPARGGPR132OXER1LTB4R2ALDH1A1 | |
| SCHEMBL11587353 | 0.81 | MEN1 (0.53) | PPARGLTB4R2ALDH1A1LTB4R | |
| SCHEMBL11587350 | 0.81 | MEN1 (0.53) | PPARGLTB4R2ALDH1A1LTB4R | |
| SCHEMBL13148470 | 0.80 | OXER1 (0.68) | PPARGGPR132OXER1LTB4R2ALDH1A1 | |
| SCHEMBL13148473 | 0.80 | OXER1 (0.68) | PPARGGPR132OXER1LTB4R2ALDH1A1 | |
| SCHEMBL3004862 | 0.78 | PPARG (0.43) | PPARGGPR132OXER1LTB4R2ALDH1A1 | |
| SCHEMBL3004869 | 0.78 | PPARG (0.43) | PPARGGPR132OXER1LTB4R2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100191019-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-07-29 | — | — | US | claimed |
| EP-2178399-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-04-28 | — | — | EP | claimed |
| WO-2009009916-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-01-22 | — | — | WO | claimed |
| US-20100191019-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2178399-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009009916-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100191019-A1 | Organic Compounds | OR10J3, ALOX5, OR51E2 | PPARG 115/4885GPR132 3709/4885OXER1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.